Collegium Pharmaceutical, Inc. (COLL) Receives Buy Rating from Jefferies Group LLC
Jefferies Group LLC reaffirmed their buy rating on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in a research report sent to investors on Thursday morning. Jefferies Group LLC currently has a $15.00 price objective on the specialty pharmaceutical company’s stock.
Several other analysts have also recently commented on the company. Zacks Investment Research cut Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Tuesday, July 11th. BidaskClub downgraded Collegium Pharmaceutical from a hold rating to a sell rating in a report on Friday, August 4th. HC Wainwright assumed coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a buy rating and a $21.00 price objective for the company. ValuEngine upgraded shares of Collegium Pharmaceutical from a strong sell rating to a sell rating in a research report on Thursday, June 22nd. Finally, Needham & Company LLC restated a buy rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, May 31st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of Hold and a consensus price target of $19.50.
Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 2.78% during midday trading on Thursday, hitting $10.34. The stock had a trading volume of 154,214 shares. Collegium Pharmaceutical has a one year low of $9.68 and a one year high of $20.55. The stock has a 50 day moving average of $10.41 and a 200-day moving average of $10.41. The company’s market cap is $305.71 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $4.07 million. Analysts forecast that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.
WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/22/collegium-pharmaceutical-inc-coll-receives-buy-rating-from-jefferies-group-llc.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in COLL. American International Group Inc. boosted its stake in Collegium Pharmaceutical by 27.8% in the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares during the period. Nationwide Fund Advisors boosted its stake in Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares during the period. Voya Investment Management LLC acquired a new position in Collegium Pharmaceutical in the 2nd quarter worth $125,000. Credit Suisse AG boosted its stake in Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares during the period. Finally, UBS Group AG boosted its stake in Collegium Pharmaceutical by 283.2% in the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the period. 83.04% of the stock is owned by hedge funds and other institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.